Targeted Therapy and Immunotherapy Use in NSCLC

Image removed.At the 23rd Annual Perspectives in Thoracic Oncology meeting held in New York, Joshua M. Bauml, MD, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania, Philadelphia, told attendees about the varying treatment options available for patients with non–small-cell lung cancer (NSCLC).

In this 3-part video series, Dr Bauml talks about targeted therapy and the use of genetic markers in NSCLC, and discusses the current and future landscape of immunotherapy for NSCLC.

Check out all 3 parts of the series with Dr Bauml below!


Genetic Markers in NSCLC

Dr Bauml discusses genetic markers found in NSCLC and how to use them to target therapy for individual patients.

Watch Here


Barriers to Using Targeted Therapy in NSCLC

Dr Bauml discusses the role of targeted therapy in NSCLC and some of the barriers to using this treatment approach.

Watch Here


Immunotherapy for NSCLC

Dr Bauml, discusses the role of immunotherapy in the current treatment landscape of NSCLC.

Watch Here


Stay in the know.
OncNet Newsletter